659. Can Marty Makary Fix the F.D.A.?

The conversation centers on Marty Makary's role as FDA Commissioner and his efforts to modernize the agency. Makary discusses addressing over-regulation, streamlining drug approval processes, and leveraging AI to improve efficiency. He highlights initiatives such as making FDA decision letters public and redefining baby formulas to promote innovation. The discussion touches on controversies, including the FDA's stance on acetaminophen use during pregnancy and direct-to-consumer pharmaceutical ads. Makary also addresses funding for public health and the challenges of navigating political influences on scientific decisions, particularly concerning vaccine efficacy and the phenomenon of "Trump Derangement Syndrome."

Outlines

Part 1: Leadership, Context, and Philosophy

Part 2: Institutional Reform and Modernization

Part 3: Medical Breakthroughs and Research Focus

Part 4: Regulatory Policy and Industry Oversight

Part 5: Politics, Funding, and Future Outlook

Sign in to continue reading, translating and more.

Open full episode in Podwise

Freakonomics Radio

Part 1: Leadership, Context, and Philosophy

Public Health Priorities Under Robert F. Kennedy Jr. and Marty Makary's FDA

Marty Makary's Transition to FDA Commissioner: Challenging Medical Dogma

FDA's Past Mistakes: OxyContin Approval and the Demonization of Natural Fats

Makary's Path to the FDA: Price Transparency Advocacy and White House Invitation

Part 2: Institutional Reform and Modernization

Makary's FDA: Addressing Overregulation and Streamlining Drug Approvals

FDA Priorities: Modernization, AI Integration, and Public Transparency

AI in Medical Diagnosing: FDA's ELSA Tool for Scientific Reviewers

Part 3: Medical Breakthroughs and Research Focus

FDA's Goal: More Meaningful Drug Approvals and Addressing Unmet Public Health Needs

Promising Research: Beta Cell Growth for Type 1 Diabetes Treatment

Autism Research: Acetaminophen Concerns and Leucovorin Treatment

Leucovorin for Autism: Data Collection and Clinical Improvements

Acetaminophen and Autism: Mixed Research and Media Coverage

Part 4: Regulatory Policy and Industry Oversight

Direct-to-Consumer Pharmaceutical Ads: Targeting Deceptive Practices

Replacing Animal Testing: Organoids and Organs-on-a-Chip for Drug Testing

Regulating Birth Control and Medical Abortion: FDA's Independence

Part 5: Politics, Funding, and Future Outlook

Public Health Funding: Media Misreporting and Partisan Culture

Navigating Controversy: Kennedy's HHS and Trump Derangement Syndrome

FDA's Focus: Cures, Economic Incentives, and User-Friendly Processes

FDA Morale and Efficiency: Hiring Scientific Reviewers and Streamlining Processes

659. Can Marty Makary Fix the F.D.A.?

Freakonomics Radio

Part 1: Leadership, Context, and Philosophy

00:34Public Health Priorities Under Robert F. Kennedy Jr. and Marty Makary's FDA

Public Health Priorities Under Robert F. Kennedy Jr. and Marty Makary's FDA

02:56Marty Makary's Transition to FDA Commissioner: Challenging Medical Dogma

Marty Makary's Transition to FDA Commissioner: Challenging Medical Dogma

04:46FDA's Past Mistakes: OxyContin Approval and the Demonization of Natural Fats

FDA's Past Mistakes: OxyContin Approval and the Demonization of Natural Fats

07:59Makary's Path to the FDA: Price Transparency Advocacy and White House Invitation

Makary's Path to the FDA: Price Transparency Advocacy and White House Invitation

Part 2: Institutional Reform and Modernization

11:46Makary's FDA: Addressing Overregulation and Streamlining Drug Approvals

Makary's FDA: Addressing Overregulation and Streamlining Drug Approvals

15:21FDA Priorities: Modernization, AI Integration, and Public Transparency

FDA Priorities: Modernization, AI Integration, and Public Transparency

17:30AI in Medical Diagnosing: FDA's ELSA Tool for Scientific Reviewers

AI in Medical Diagnosing: FDA's ELSA Tool for Scientific Reviewers

Part 3: Medical Breakthroughs and Research Focus

20:27FDA's Goal: More Meaningful Drug Approvals and Addressing Unmet Public Health Needs

FDA's Goal: More Meaningful Drug Approvals and Addressing Unmet Public Health Needs

23:45Promising Research: Beta Cell Growth for Type 1 Diabetes Treatment

Promising Research: Beta Cell Growth for Type 1 Diabetes Treatment

27:42Autism Research: Acetaminophen Concerns and Leucovorin Treatment

Autism Research: Acetaminophen Concerns and Leucovorin Treatment

30:30Leucovorin for Autism: Data Collection and Clinical Improvements

Leucovorin for Autism: Data Collection and Clinical Improvements

33:34Acetaminophen and Autism: Mixed Research and Media Coverage

Acetaminophen and Autism: Mixed Research and Media Coverage

Part 4: Regulatory Policy and Industry Oversight

37:30Direct-to-Consumer Pharmaceutical Ads: Targeting Deceptive Practices

Direct-to-Consumer Pharmaceutical Ads: Targeting Deceptive Practices

39:40Replacing Animal Testing: Organoids and Organs-on-a-Chip for Drug Testing

Replacing Animal Testing: Organoids and Organs-on-a-Chip for Drug Testing

42:17Regulating Birth Control and Medical Abortion: FDA's Independence

Regulating Birth Control and Medical Abortion: FDA's Independence

Part 5: Politics, Funding, and Future Outlook

45:31Public Health Funding: Media Misreporting and Partisan Culture

Public Health Funding: Media Misreporting and Partisan Culture

47:51Navigating Controversy: Kennedy's HHS and Trump Derangement Syndrome

Navigating Controversy: Kennedy's HHS and Trump Derangement Syndrome

50:52FDA's Focus: Cures, Economic Incentives, and User-Friendly Processes

FDA's Focus: Cures, Economic Incentives, and User-Friendly Processes

53:28FDA Morale and Efficiency: Hiring Scientific Reviewers and Streamlining Processes

FDA Morale and Efficiency: Hiring Scientific Reviewers and Streamlining Processes